Agilent and Groton Signs Co-Marketing Agreement for Pharmaceutical Manufacturing Solutions
News Jan 19, 2007
Agilent Technologies Inc. and Groton Biosystems LLC have announced an agreement to co-market solutions for the Process Analytical Technology (PAT) initiative for the pharmaceutical industry in the United States and Canada.
PAT is a system for designing, analyzing and controlling manufacturing by measuring critical quality and performance attributes of raw and in-process materials and processes, all with the goal of ensuring final product quality.
The alliance is designed to benefit biopharmaceutical customers who perform in-process and final product testing in a wide range of production segments and who are looking for online sampling with HPLC analysis for rapid quality-related decision-making.
The agreement, expected to expand to Europe and Asia in the near future, brings together Agilent’s world-class HPLC systems with Groton Biosystems’ strong online sampling products and services.
"Our joint customers in the pharmaceutical industry require a high degree of integration and automation," said Nick Roelofs, vice president and general manager, Life Sciences Solutions Unit, at Agilent Technologies.
"This agreement will enable us to deliver better, faster solutions to our mutual customers in the biopharmaceutical industry and increase the quality of final products in manufacturing."
"The PAT initiative is becoming a major driving force in the pharma industry," added Groton Biosystems CEO Bill Dinardo.
"The elimination of human intervention in online sample acquisition and analysis steps will save labor, reduce the risk of contamination and minimize the potential for error. This collaboration was driven by a strong demand from industry leaders and from current Agilent HPLC users."
Under the terms of the agreement, Agilent and Groton Biosystems will jointly market 1200 Series HPLC solutions with Groton Biosystems’ Automated Reactor Sampling ARS Series On-line Process Autosampling products within the U.S. and Canada, including pre- and post-sales activities, such as product presentations, trade show participation and customer events.
Researchers have developed an artificial enzymatic pathway for synthesizing isoprenoids, or terpenes, in E. coli. This shorter, more efficient, cost-effective and customizable pathway transforms E. coli into a factory that can produce terpenes for use in everything from cancer drugs to biofuels.READ MORE
2nd International Conference on Pharmaceutical Research & Innovations in Pharma Industry
May 30 - May 31, 2019